Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH (Non-Alcoholic Steatohepatitis) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production

NCT01262326
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Calorie and Carbohydrate Restriction
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 9, 2026, 3:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

NCT03863574
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
El Cajon, California • Murrieta, California • Rialto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

NCT05935826
View directory record Official record
Conditions
Hepatic Steatosis, NAFLD, Adolescent Obesity
Interventions
Essential Amino Acid Supplement by Amino Co, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376
View directory record Official record
Conditions
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Silymarin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 9, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Results available

Amlexanox for Type 2 Diabetes and Obesity

NCT01842282
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Not applicable Interventional

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

NCT06215131
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
Interventions
In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 9, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Seladelpar, Placebos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease

NCT00714129
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Diabetes
Interventions
Dietary intervention (calorie restricted diet)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 9, 2026, 3:59 PM EDT
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 9, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Results available

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
AZ compound, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 9, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682
View directory record Official record
Conditions
Steatohepatitis
Interventions
Ontamalimab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 9, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Results available

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

NCT01244503
View directory record Official record
Conditions
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Interventions
Sodium Octanoate Breath Test
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

NCT03445208
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 9, 2026, 3:59 PM EDT
Active, not recruiting No phase listed Observational

Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study

NCT02754037
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer
Radiation · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 9, 2026, 3:59 PM EDT
Withdrawn No phase listed Observational

Assessment of Fatty Liver With Thermo-acoustic Device

NCT04302051
View directory record Official record
Conditions
NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Fatty Liver, Fatty Liver Disease
Interventions
Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03938246
View directory record Official record
Conditions
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Interventions
TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US)
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Chula Vista, California • Montclair, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05989711
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
Pemvidutide, Placebo
Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alternate Day Fasting, Exercise, and NAFLD

NCT04004403
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Alternate day fasting, Exercise
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 9, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Anti-LPS Antibody Treatment for Pediatric NAFLD

NCT03042767
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
IMM-124E, Placebo
Biological · Other
Lead sponsor
Miriam Vos, MD
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 9, 2026, 3:59 PM EDT